Showing 2231-2240 of 5623 results for "".
- Otsuka and ShapeTX Collaborate to Develop AAV Gene Therapies for Ocular Diseaseshttps://modernod.com/news/otsuka-and-shapetx-collaborate-to-develop-aav-gene-therapies-for-ocular-diseases/2481832/Otsuka Pharmaceutical and ShapeTX, a programmable medicine company using artificial intelligence (AI) and RNA to combat genetic diseases, announced a multitarget collaboration to develop intravitreally delivered adeno-associated viruses (AAVs) for ocular diseases, with options to add additional t
- Study Finds Role of Biosynthetic Fatty Acid Pathway Insufficiencies in Age-Related Macular Degenerationhttps://modernod.com/news/study-finds-role-of-biosynthetic-fatty-acid-pathway-insufficiencies-in-age-related-macular-degeneration/2481831/LSU Health Sciences Center announced the publication of findings that suggest that age-related macular degeneration (AMD) decreases an essential fatty acid, preventing the formation of a class of protective molecules and reducing repair potential. The research was led by Nicolas Bazan,
- Link Biologics and Théa Open Innovation Enter Partnership to Develop Drug Candidate for Dry Eye Diseasehttps://modernod.com/news/link-biologics-and-thea-open-innovation-enter-partnership-to-develop-drug-candidate-for-dry-eye-disease/2481828/Link Biologics Limited and Théa Open Innovation announced that they have entered into an agreement to co-develop Link_TSG6 for the treatment of dry eye disease (DED) and other ophthalmology indications, worldwide excluding Asia. Link_TSG6 is a biological drug based on human TSG-6
- Novartis to Discontinue Development of GA Gene Therapyhttps://modernod.com/news/novartis-to-discontinue-development-of-ga-gene-therapy/2481824/Following weak phase 2 clinical data, Novartis decided to discontinue the clinical development of its geographic atrophy gene therapy candidate GT005, which it acquired as part of its acquisition of Gyroscope Therapeutics. The announcement was made by investment film Syncona, which prev
- Award-Winning Actress, Dancer and Director Debbie Allen Joins Prevent Blindness and Regeneron to Raise Awareness of Serious Retinal Diseaseshttps://modernod.com/news/award-winning-actress-dancer-and-director-debbie-allen-joins-prevent-blindness-and-regeneron-to-raise-awareness-of-serious-retinal-diseases/2481818/Award-winning actress, dancer and director Debbie Allen is partnering with Prevent Blindness and Regeneron to launch the 'Gr8 Eye Movement,' a new disease awareness campaign that aims to address gaps in how people understand the risk of developing certain serious retinal di
- Myra Vision Announces First-in-Human Use of its Calibreye Glaucoma Drainage Devicehttps://modernod.com/news/myra-vision-announces-first-in-human-use-of-its-calibreye-glaucoma-drainage-device/2481816/Myra Vision announced it has initiated its first-in-human clinical study of the Calibreye System, a glaucoma drainage device with titratable outflow control designed to achieve optimal reduction of IOP for moderate to severe glaucoma patients. The prospective, non-randomized open-label
- Ciliatech Presents Preliminary 1-Year Study Results on Treating Open and Narrow Angle Glaucoma with CIDhttps://modernod.com/news/ciliatech-presents-preliminary-1-year-study-results-on-treating-open-and-narrow-angle-glaucoma-with-cid/2481814/Ciliatech announced it will present at the Ophthalmology Futures Symposium the preliminary results of a 1-year study of its clinical trial, SAFARI III, involving both open and narrow angle glaucoma patients. Preliminary outcomes show an excellent performance and safety profile, wit
- DigitalOptometrics to Demonstrate Its Remote Comprehensive Exam Services With Instant Language Translation Capabilities at Vision Expo Westhttps://modernod.com/news/digitaloptometrics-to-demonstrate-its-remote-comprehensive-exam-services-with-instant-language-translation-capabilities-at-vision-expo-west/2481811/DigitalOptometrics, a provider of remote comprehensive eye exam services, will demonstrate its technology at Vision Expo West, September 28-30. Attendees can interact with a remote optometrist in real-time and experience a patient-centric comprehensive eye exam conducted via high-definition
- SightGlass Vision Reports 4-Year Clinical Trial Outcomes for Myopia Control DOT Spectacle Lenseshttps://modernod.com/news/sightglass-vision-reports-4-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses/2481810/SightGlass Vision reported positive 4-year outcomes from its pivotal CYPRESS study extension, which is evaluating the myopia control performance of the company’s Diffusion Optics Technology (DOT 0.2) spectacle lenses. The lenses use thousands of light scattering el
- Tarsus Launches Demodex Blepharitis Treatment Xdemvyhttps://modernod.com/news/tarsis-launches-demodex-blepharitis-treatment-xdemvy/2481792/Tarsus Pharmaceuticals announced that Xdemvy (lotilaner ophthalmic solution 0.25%) is now available at pharmacies nationwide for prescription. The FDA approved Xdemvy on July 24, 2023, for the treatment of Demodex blepharitis. “We are delighted that w